Table of Contents Author Guidelines Submit a Manuscript
Sarcoma
Volume 2012, Article ID 152382, 9 pages
http://dx.doi.org/10.1155/2012/152382
Review Article

At-Risk Populations for Osteosarcoma: The Syndromes and Beyond

1Department of Orthopaedics and Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT 84112, USA
2Sarcoma Services, Center for Children, Huntsman Cancer Institute, The University of Utah, Salt Lake City, UT 84112, USA
3Division of Genetic Epidemiology, Department of Biomedical Informatics, University of Utah School of Medicine, Salt Lake City, Utah 84108, USA
4Division of Pediatric Hematology Oncology, Department of Pediatrics, The University of Utah, Salt Lake City, UT 84112, USA

Received 15 October 2011; Accepted 17 November 2011

Academic Editor: Alessandro Gronchi

Copyright © 2012 George T. Calvert et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. L. Mirabello, R. J. Troisi, and S. A. Savage, “International osteosarcoma incidence patterns in children and adolescents, middle ages and elderly persons,” International Journal of Cancer, vol. 125, no. 1, pp. 229–234, 2009. View at Publisher · View at Google Scholar · View at Scopus
  2. S. A. Savage and L. Mirabello, “Using epidemiology and genomics to understand osteosarcoma etiology,” Sarcoma, vol. 2011, Article ID 548151, 13 pages, 2011. View at Publisher · View at Google Scholar
  3. E. I. Hauben, J. Arends, J. P. Vandenbroucke, C. J. van Asperen, E. Van Marck, and P. C. W. Hogendoorn, “Multiple primary malignancies in osteosarcoma patients. Incidence and predictive value of osteosarcoma subtype for cancer syndromes related with osteosarcoma,” European Journal of Human Genetics, vol. 11, no. 8, pp. 611–618, 2003. View at Publisher · View at Google Scholar · View at Scopus
  4. J. Ji and K. Hemminki, “Familial risk for histology-specific bone cancers: an updated study in Sweden,” European Journal of Cancer, vol. 42, no. 14, pp. 2343–2349, 2006. View at Publisher · View at Google Scholar
  5. F. P. Li and J. F. Fraumeni, “Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome?” Annals of Internal Medicine, vol. 71, no. 4, pp. 747–752, 1969. View at Google Scholar · View at Scopus
  6. S. Srivastava, Z. Zou, K. Pirollo, W. Blattner, and E. H. Chang, “Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome,” Nature, vol. 348, no. 6303, pp. 747–749, 1990. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Malkin, F. P. Li, L. C. Strong et al., “Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms,” Science, vol. 250, no. 4985, pp. 1233–1238, 1990. View at Google Scholar · View at Scopus
  8. J. A. Royds and B. Iacopetta, “p53 and disease: when the guardian angel fails,” Cell Death and Differentiation, vol. 13, no. 6, pp. 1017–1026, 2006. View at Publisher · View at Google Scholar · View at Scopus
  9. J. M. Birch, A. L. Hartley, K. J. Tricker et al., “Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families,” Cancer Research, vol. 54, no. 5, pp. 1298–1304, 1994. View at Google Scholar · View at Scopus
  10. J. E. Garber, A. M. Goldstein, A. F. Kantor, M. G. Dreyfus, J. F. Fraumeni, and F. P. Li, “Follow-up study of twenty-four families with Li-Fraumeni syndrome,” Cancer Research, vol. 51, no. 22, pp. 6094–6097, 1991. View at Google Scholar · View at Scopus
  11. D. G. Evans, J. M. Birch, and S. A. Narod, “Is CHEK2 a cause of the Li-Fraumeni syndrome?” Journal of Medical Genetics, vol. 45, no. 1, pp. 63–64, 2008. View at Publisher · View at Google Scholar · View at Scopus
  12. M. W. G. Ruijs, A. Broeks, F. H. Menko et al., “The contribution of CHEK2 to the TP53-negative Li-Fraumeni phenotype,” Hereditary Cancer in Clinical Practice, vol. 7, no. 1, article 4, 2009. View at Publisher · View at Google Scholar
  13. F. P. Li, J. F. Fraumeni, J. J. Mulvihill et al., “A cancer family syndrome in twenty-four kindreds,” Cancer Research, vol. 48, no. 18, pp. 5358–5362, 1988. View at Google Scholar · View at Scopus
  14. J. M. Birch, A. L. Hartley, K. J. Tricker et al., “Prevalence and diversity of constitutional mutations in the p53 gene among 21 Li-Fraumeni families,” Cancer Research, vol. 54, no. 5, pp. 1298–1304, 1994. View at Google Scholar · View at Scopus
  15. M. Olivier, D. E. Goldgar, N. Sodha et al., “Li-fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype,” Cancer Research, vol. 63, no. 20, pp. 6643–6650, 2003. View at Google Scholar · View at Scopus
  16. S. Ognjanovic, M. Oliver, T. L. Bergemann, and P. Hainaut, “Sarcomas in TP53 germline mutation carriers: a review of the IARC TP53 database,” Cancer. In press. View at Publisher · View at Google Scholar
  17. U. Tabori and D. Malkin, “Risk stratification in cancer predisposition syndromes: lessons learned from novel molecular developments in Li-Fraumeni syndrome,” Cancer Research, vol. 68, no. 7, pp. 2053–2057, 2008. View at Publisher · View at Google Scholar · View at Scopus
  18. P. F. M. Choong, M. L. Broadhead, J. C. M. Clark, D. E. Myers, and C. R. Dass, “The molecular pathogenesis of osteosarcoma: a review,” Sarcoma, vol. 2011, Article ID 959248, 12 pages, 2011. View at Publisher · View at Google Scholar
  19. L. L. Wang, “Biology of osteogenic sarcoma,” Cancer Journal, vol. 11, no. 4, pp. 294–305, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. D. G. R. Evans, J. M. Birch, R. T. Ramsden, S. Sharif, and M. E. Baser, “Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes,” Journal of Medical Genetics, vol. 43, no. 4, pp. 289–294, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. S. Heymann, S. Delaloge, A. Rahal et al., “Radio-induced malignancies after breast cancer postoperative radiotherapy in patients with Li-Fraumeni syndrome,” Radiation Oncology, vol. 5, no. 1, article 104, 2010. View at Publisher · View at Google Scholar
  22. J. Monsalve, J. Kapur, D. Malkin, and P. S. Babyn, “Imaging of cancer predisposition syndromes in children,” Radiographics, vol. 31, no. 1, pp. 263–280, 2011. View at Publisher · View at Google Scholar
  23. A. Villani, U. Tabori, J. Schiffman et al., “Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study,” The Lancet Oncology, vol. 12, no. 6, pp. 559–567, 2011. View at Publisher · View at Google Scholar
  24. A. Chompret, A. Abel, D. Stoppa-Lyonnet et al., “Sensitivity and predictive value of criteria for p53 germline mutation screening,” Journal of Medical Genetics, vol. 38, no. 1, pp. 43–47, 2001. View at Google Scholar · View at Scopus
  25. J. Tinat, G. Bougeard, S. Baert-Desurmont et al., “2009 version of the Chompret criteria for Li Fraumeni syndrome,” Journal of Clinical Oncology, vol. 27, no. 26, pp. e108–e109, 2009. View at Publisher · View at Google Scholar
  26. J. N. Weitzel, K. D. Gonzalez, K. A. Noltner et al., “Beyond li fraumeni syndrome: clinical characteristics of families with p53 germline mutations,” Journal of Clinical Oncology, vol. 27, no. 8, pp. 1250–1256, 2009. View at Publisher · View at Google Scholar
  27. M. A. Dyer and R. Bremner, “The search for the retinoblastoma cell of origin,” Nature Reviews Cancer, vol. 5, no. 2, pp. 91–101, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Kivelä, “The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death,” British Journal of Ophthalmology, vol. 93, no. 9, pp. 1129–1131, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. E. Broaddus, A. Topham, and A. D. Singh, “Survival with retinoblastoma in the USA: 1975–2004,” British Journal of Ophthalmology, vol. 93, no. 1, pp. 24–27, 2009. View at Publisher · View at Google Scholar · View at Scopus
  30. C. L. Shields and J. A. Shields, “Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy,” Current Opinion in Ophthalmology, vol. 21, no. 3, pp. 203–212, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. A. G. Knudson, “Mutation and cancer: statistical study of retinoblastoma,” Proceedings of the National Academy of Sciences of the United States of America, vol. 68, no. 4, pp. 820–823, 1971. View at Google Scholar · View at Scopus
  32. S. H. Friend, R. Bernards, and S. Rogelj, “A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma,” Nature, vol. 323, no. 6089, pp. 643–646, 1986. View at Google Scholar · View at Scopus
  33. A. MacCarthy, A. M. Bayne, G. J. Draper et al., “Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004,” British Journal of Ophthalmology, vol. 93, no. 9, pp. 1159–1162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. K. B. Jones, “Osteosarcomagenesis: modeling cancer initiation in the mouse,” Sarcoma, vol. 2011, Article ID 694136, 10 pages, 2011. View at Publisher · View at Google Scholar
  35. G. Ottaviani and N. Jaffe, “The etiology of osteosarcoma,” Cancer Treatment and Research, vol. 152, pp. 15–32, 2009. View at Publisher · View at Google Scholar · View at Scopus
  36. G. P. Nielsen, K. L. Burns, A. E. Rosenberg, and D. N. Louis, “CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations,” American Journal of Pathology, vol. 153, no. 1, pp. 159–163, 1998. View at Google Scholar · View at Scopus
  37. M. Serena Benassi, L. Molendini, G. Gamberi et al., “Alteration of prb/p16/cdk4 regulation in human osteosarcoma,” International Journal of Cancer, vol. 84, no. 5, pp. 489–493, 1999. View at Google Scholar · View at Scopus
  38. G. Wei, F. Lonardo, T. Ueda et al., “CDK4 gene amplification in osteosarcoma: reciprocal relationship with INK4A gene alterations and mapping of 12q13 amplicons,” International Journal of Cancer, vol. 80, no. 2, pp. 199–204, 1999. View at Publisher · View at Google Scholar · View at Scopus
  39. A. MacCarthy, A. M. Bayne, G. J. Draper et al., “Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004,” British Journal of Ophthalmology, vol. 93, no. 9, pp. 1159–1162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  40. F. L. Wong, J. D. Boice, D. H. Abramson et al., “Cancer incidence after retinoblastoma: radiation dose and sarcoma risk,” JAMA, vol. 278, no. 15, pp. 1262–1267, 1997. View at Google Scholar · View at Scopus
  41. O. Fletcher, D. Easton, K. Anderson, C. Gilham, M. Jay, and J. Peto, “Lifetime risks of common cancers among retinoblastoma survivors,” Journal of the National Cancer Institute, vol. 96, no. 5, pp. 357–363, 2004. View at Google Scholar · View at Scopus
  42. O. Fletcher, D. Easton, K. Anderson, C. Gilham, M. Jay, and J. Peto, “Lifetime risks of common cancers among retinoblastoma survivors,” Journal of the National Cancer Institute, vol. 96, no. 5, pp. 357–363, 2004. View at Google Scholar · View at Scopus
  43. A. MacCarthy, A. M. Bayne, G. J. Draper et al., “Non-ocular tumours following retinoblastoma in Great Britain 1951 to 2004,” British Journal of Ophthalmology, vol. 93, no. 9, pp. 1159–1162, 2009. View at Publisher · View at Google Scholar · View at Scopus
  44. C. L. Shields and J. A. Shields, “Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy,” Current Opinion in Ophthalmology, vol. 21, no. 3, pp. 203–212, 2010. View at Publisher · View at Google Scholar
  45. A. Patiño-García, E. Sotillo Piñeiro, M. Zalacaín Díez, L. Gárate Iturriagagoitia, F. Antillón Klüssmann, and L. Sierrasesúmaga Ariznabarreta, “Genetic and epigenetic alterations of the cell cycle regulators and tumor suppressor genes in pediatric osteosarcomas,” Journal of Pediatric Hematology/Oncology, vol. 25, no. 5, pp. 362–367, 2003. View at Publisher · View at Google Scholar
  46. M. V. Parulekar, “Retinoblastoma—current treatment and future direction,” Early Human Development, vol. 86, no. 10, pp. 619–625, 2010. View at Publisher · View at Google Scholar · View at Scopus
  47. V. Sheen, M. A. Tucker, D. H. Abramson, J. M. Seddon, and R. A. Kleinerman, “Cancer screening practices of adult survivors of retinoblastoma at risk of second cancers,” Cancer, vol. 113, no. 2, pp. 434–441, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. C. Serrano, J. Alonso, G. Gómez-Mariano et al., “Low penetrance hereditary retinoblastoma in a family: what should we consider in the genetic counselling process and follow up?” Familial Cancer, vol. 10, no. 3, pp. 617–621, 2011. View at Publisher · View at Google Scholar
  49. S. S. Bruinooge, “American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility,” Journal of Clinical Oncology, vol. 21, no. 12, pp. 2397–2406, 2003. View at Publisher · View at Google Scholar · View at Scopus
  50. D. H. Abramson, K. Beaverson, P. Sangani et al., “Screening for retinoblastoma: presenting signs as prognosticators of patient and ocular survival,” Pediatrics, vol. 112, no. 6, pp. 1248–1255, 2003. View at Publisher · View at Google Scholar · View at Scopus
  51. K. C. Sippel, R. E. Fraioli, G. D. Smith et al., “Frequency of somatic and germ-line mosaicism in retinoblastoma: implications for genetic counseling,” American Journal of Human Genetics, vol. 62, no. 3, pp. 610–619, 1998. View at Publisher · View at Google Scholar · View at Scopus
  52. V. A. Bohr, “Rising from the RecQ-age: the role of human RecQ helicases in genome maintenance,” Trends in Biochemical Sciences, vol. 33, no. 12, pp. 609–620, 2008. View at Publisher · View at Google Scholar · View at Scopus
  53. R. J. Monnat Jr., “Human RECQ helicases: roles in DNA metabolism, mutagenesis and cancer biology,” Seminars in Cancer Biology, vol. 20, no. 5, pp. 329–339, 2010. View at Publisher · View at Google Scholar · View at Scopus
  54. L. L. Wang, M. L. Levy, R. A. Lewis et al., “Clinical manifestations in a cohort of 41 Rothmund-Thomson syndrome patients,” American Journal of Medical Genetics, vol. 102, no. 1, pp. 11–17, 2001. View at Publisher · View at Google Scholar · View at Scopus
  55. S. Kitao, A. Shimamoto, M. Goto et al., “Mutations in RECQL4 cause a subset of cases of Rothmund-Thomson syndrome,” Nature Genetics, vol. 22, no. 1, pp. 82–84, 1999. View at Publisher · View at Google Scholar · View at Scopus
  56. L. Larizza, G. Roversi, and L. Volpi, “Rothmund-thomson syndrome,” Orphanet Journal of Rare Diseases, vol. 5, no. 1, article 2, 2010. View at Publisher · View at Google Scholar · View at Scopus
  57. M. A. Macris, L. Krejci, W. Bussen, A. Shimamoto, and P. Sung, “Biochemical characterization of the RECQ4 protein, mutated in Rothmund-Thomson syndrome,” DNA Repair, vol. 5, no. 2, pp. 172–180, 2006. View at Publisher · View at Google Scholar · View at Scopus
  58. G. Stinco, G. Governatori, P. Mattighello, and P. Patrone, “Multiple cutaneous neoplasms in a patient with Rothmund-Thomson syndrome: case report and published work review,” The Journal of Dermatology, vol. 35, no. 3, pp. 154–161, 2008. View at Publisher · View at Google Scholar · View at Scopus
  59. L. L. Wang, A. Gannavarapu, C. A. Kozinetz et al., “Association between osteosarcoma and deleterious mutations in the RECQL4 gene Rothmund-Thomson syndrome,” Journal of the National Cancer Institute, vol. 95, no. 9, pp. 669–674, 2003. View at Google Scholar · View at Scopus
  60. H. Kääriäinen, S. Ryoppy, and R. Norio, “RAPADILIMO syndrome with radial and patellar aplasia/hypoplasia as main manifestations,” American Journal of Medical Genetics, vol. 33, no. 3, pp. 346–351, 1989. View at Google Scholar · View at Scopus
  61. H. A. Siitonen, O. Kopra, H. Kääriäinen et al., “Molecular defect of RAPADILINO syndrome expands the phenotype spectrum of RECQL diseases,” Human Molecular Genetics, vol. 12, no. 21, pp. 2837–2844, 2003. View at Publisher · View at Google Scholar · View at Scopus
  62. A. H. Siitonen, J. Sotkasiira, M. Biervliet et al., “The mutation spectrum in RECQL4 diseases,” European Journal of Human Genetics, vol. 17, no. 2, pp. 151–158, 2009. View at Publisher · View at Google Scholar · View at Scopus
  63. J. Nakura, E. M. Wijsman, T. Miki et al., “Homozygosity mapping of the Werner syndrome locus (WRN),” Genomics, vol. 23, no. 3, pp. 600–608, 1994. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Goto, “Hierarchical deterioration of body systems in Werner's syndrome: implications for normal ageing,” Mechanisms of Ageing and Development, vol. 98, no. 3, pp. 239–254, 1997. View at Publisher · View at Google Scholar · View at Scopus
  65. C. E. Yu, J. Oshima, Y. H. Fu et al., “Positional cloning of the Werner's syndrome gene,” Science, vol. 272, no. 5259, pp. 258–262, 1996. View at Google Scholar · View at Scopus
  66. M. Goto, R. W. Miller, Y. Ishikawa, and H. Sugano, “Excess of rare cancers in Werner syndrome (adult progeria),” Cancer Epidemiology, Biomarkers & Prevention, vol. 5, no. 4, pp. 239–246, 1996. View at Google Scholar
  67. Y. Ishikawa, R. W. Miller, R. Machinami, H. Sugano, and M. Goto, “Atypical osteosarcomas in Werner Syndrome (Adult Progeria),” Japanese Journal of Cancer Research, vol. 91, no. 12, pp. 1345–1349, 2000. View at Google Scholar · View at Scopus
  68. N. A. Ellis, J. Groden, T. Z. Ye et al., “The Bloom's syndrome gene product is homologous to RecQ helicases,” Cell, vol. 83, no. 4, pp. 655–666, 1995. View at Google Scholar · View at Scopus
  69. N. A. Ellis, S. Ciocci, M. Proytcheva, D. Lennon, J. Groden, and J. German, “The Ashkenazic Jewish bloom syndrome mutation blm(Ash) is present in non-Jewish Americans of Spanish ancestry,” American Journal of Human Genetics, vol. 63, no. 6, pp. 1685–1693, 1998. View at Publisher · View at Google Scholar · View at Scopus
  70. J. German, “Bloom's syndrome. XX. The first 100 cancers,” Cancer Genetics and Cytogenetics, vol. 93, no. 1, pp. 100–106, 1997. View at Publisher · View at Google Scholar · View at Scopus
  71. L. Li, C. Eng, R. J. Desnick, J. German, and N. A. Ellis, “Carrier frequency of the Bloom syndrome blm(Ash) mutation in the Ashkenazi Jewish population,” Molecular Genetics and Metabolism, vol. 64, no. 4, pp. 286–290, 1998. View at Publisher · View at Google Scholar · View at Scopus
  72. J. M. Lipton, E. Atsidaftos, I. Zyskind, and A. Vlachos, “Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry,” Pediatric Blood and Cancer, vol. 46, no. 5, pp. 558–564, 2006. View at Publisher · View at Google Scholar · View at Scopus
  73. A. Vlachos, S. Ball, N. Dahl et al., “Diagnosing and treating Diamond Blackfan anaemia: results of an international clinical consensus conference,” British Journal of Haematology, vol. 142, no. 6, pp. 859–876, 2008. View at Publisher · View at Google Scholar · View at Scopus
  74. L. Doherty, M. R. Sheen, A. Vlachos et al., “Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia,” American Journal of Human Genetics, vol. 86, no. 2, pp. 222–228, 2010. View at Publisher · View at Google Scholar · View at Scopus
  75. N. Draptchinskaia, P. Gustavsson, B. Andersson et al., “The gene encoding ribosomal protein S19 is mutated in Diamond-Blackfan anaemia,” Nature Genetics, vol. 21, no. 2, pp. 169–175, 1999. View at Publisher · View at Google Scholar · View at Scopus
  76. R. S. Lee, D. Higgs, O. Haddo, J. Pringle, and T. W. R. Briggs, “Osteosarcoma associated with Diamond-Blackfan anaemia: a case of a child receiving growth hormone therapy,” Sarcoma, vol. 8, no. 1, pp. 47–49, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. J. H. M. Merks, H. N. Caron, and R. C. M. Hennekam, “High incidence of malformation syndromes in a series of 1,073 children with cancer,” American Journal of Medical Genetics, vol. 134, no. 2, pp. 132–143, 2005. View at Publisher · View at Google Scholar · View at Scopus
  78. A. Villani, U. Tabori, J. Schiffman et al., “Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study,” The Lancet Oncology, vol. 12, no. 6, pp. 559–567, 2011. View at Publisher · View at Google Scholar